<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04423198</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN01001</org_study_id>
    <nct_id>NCT04423198</nct_id>
  </id_info>
  <brief_title>HEAD Injury Serum Markers and Multi-modalities for Assessing Response to Trauma</brief_title>
  <acronym>HeadSMART II</acronym>
  <official_title>HEAD Injury Serum Markers and Multi-modalities for Assessing Response to Trauma II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BRAINBox Solutions Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BRAINBox Solutions Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of HeadSMART II (HEAD injury Serum markers and Multi-modalities for Assessing&#xD;
      Response to Trauma II) is to develop an In-Vitro Diagnostic, the BRAINBox TBI test, to aid in&#xD;
      the diagnosis and prognosis of patients with mild traumatic brain injury, by incorporating&#xD;
      blood biomarkers, clinical assessments, and tools to measure associated neurocognitive&#xD;
      impairments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study proposes to collect data using a multi-modality approach including blood&#xD;
      biomarkers, clinical assessments, neurocognitive performance, and neuropsychological&#xD;
      characteristics, to identify subjects with a mild Traumatic Brain Injury (TBI) and their&#xD;
      likelihood of chronic symptoms.&#xD;
&#xD;
      This is an observational study with an expectation of enrolling up to 2000 subjects. These&#xD;
      subjects will include the intended use population, subjects presenting to the Emergency&#xD;
      Department or Urgent Care with a blunt head trauma. Data will be collected across four time&#xD;
      points, T=0, 14 days, 30 days and 90 days, to allow for building and validating the&#xD;
      algorithms for both diagnosis and prognosis claims.&#xD;
&#xD;
      Control populations, healthy and trauma only (no head trauma) will be included for assay&#xD;
      development. Data will be collected for these groups at T=0 and 14 days (trauma control&#xD;
      only).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of mild traumatic brain injury diagnosis using the BRAINBox TBI Test compared to the Expert Clinical Diagnosis</measure>
    <time_frame>30 days</time_frame>
    <description>Sensitivity and specificity of the diagnosis as compared to a clinical diagnosis by an expert committee</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the risk stratification of having symptoms at 14, 30 and 90 days, for subjects with mild traumatic brain injury using the BRAINBox TBI Test results.</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Sensitivity and specificity of the risk for chronic symptoms as compared to the post-concussion symptoms at predefined time points</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Mild Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Target Condition</arm_group_label>
    <description>Subjects presenting to the Emergency Department (ED) or Urgent Care (UC) with a blunt head trauma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trauma Control</arm_group_label>
    <description>Subjects presenting to the ED or UC requiring an Xray but do not have a head trauma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>Subjects that are healthy and not taking any prescription medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Assessment</intervention_name>
    <description>Self administered cognitive battery</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>Target Condition</arm_group_label>
    <arm_group_label>Trauma Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Patient Reported Neurological Outcome Assessments</intervention_name>
    <description>Standard neurocognitive and neuropsychological tests</description>
    <arm_group_label>Target Condition</arm_group_label>
    <arm_group_label>Trauma Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>Specimen collection of whole blood, serum, RNA</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>Target Condition</arm_group_label>
    <arm_group_label>Trauma Control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Specimen Samples for the analysis of biomarkers include:&#xD;
&#xD;
        1. Serum&#xD;
&#xD;
        2. RNA&#xD;
&#xD;
        3. Whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects presenting to the Emergency Department or Urgent Care with a blunt head trauma.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Target Condition Subjects&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;=18 years&#xD;
&#xD;
          2. Ability to provide a blood sample; within 96 hours of injury&#xD;
&#xD;
          3. Ability to provide informed consent. Consent may be obtained with assistance of a&#xD;
             legally authorized representative (LAR)&#xD;
&#xD;
          4. Must present to the Emergency Department (ED) or Urgent Care (UC) with a blunt head&#xD;
             trauma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Glasgow Coma Scale (GCS) score &lt; 13, as presented in ED at time of screening&#xD;
&#xD;
          2. Need for general anesthesia at the time of presentation in the ED&#xD;
&#xD;
          3. Diagnosed dementia requiring assistance for daily living&#xD;
&#xD;
          4. Any head trauma requiring medical attention from a physician within the last 6 months&#xD;
&#xD;
          5. Received chemotherapy or radiation within the last year&#xD;
&#xD;
          6. History of stroke with disabling outcomes, brain tumor, epilepsy or intracranial&#xD;
             surgery/hemorrhage&#xD;
&#xD;
          7. Psychiatric hospitalization in the last 90 days&#xD;
&#xD;
          8. Blood transfusion within the prior 4 weeks&#xD;
&#xD;
          9. Non-working telephone number&#xD;
&#xD;
         10. Current participant in an interventional clinical trial&#xD;
&#xD;
         11. Cannot perform study tasks on an iPad (e.g. not wearing corrective lenses necessary to&#xD;
             read, inability to use both hands)&#xD;
&#xD;
         12. Subject considered unsuitable for participation in this clinical trial by PI, treating&#xD;
             clinician or research study staff&#xD;
&#xD;
        Control Subjects&#xD;
&#xD;
        Inclusion:&#xD;
&#xD;
          1. Age &gt;=18 years&#xD;
&#xD;
          2. Ability to provide a blood sample; (For Trauma Controls (TC's) within 96 hours of&#xD;
             injury)&#xD;
&#xD;
          3. Ability to provide informed consent. (For TC's consent may be obtained with assistance&#xD;
             of a legally authorized representative (LAR)&#xD;
&#xD;
          4. Presents to the Emergency Department or Urgent Care with at least one injury requiring&#xD;
             an X-Ray (TC's only)&#xD;
&#xD;
          5. Healthy and not taking prescription medications (Healthy Controls (HC's) only)&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. Head trauma or symptoms with head trauma at presentation&#xD;
&#xD;
          2. Head trauma requiring medical attention from a physician within the last 6 months&#xD;
&#xD;
          3. Internal organ injury (e.g. liver laceration, pulmonary contusion, spinal cord injury)&#xD;
             that requires inpatient hospitalization&#xD;
&#xD;
          4. Need for general anesthesia at the time of presentation in the ED&#xD;
&#xD;
          5. Diagnosed dementia requiring assistance for daily living&#xD;
&#xD;
          6. Received chemotherapy or radiation within the last year&#xD;
&#xD;
          7. History of stroke with disabling outcomes, brain tumor, epilepsy or intracranial&#xD;
             surgery/hemorrhage&#xD;
&#xD;
          8. Psychiatric hospitalization in the last 90 days&#xD;
&#xD;
          9. Blood transfusion within the prior 4 weeks&#xD;
&#xD;
         10. Non-working telephone number&#xD;
&#xD;
         11. Current participant in an interventional clinical trial&#xD;
&#xD;
         12. Cannot perform study tasks on an iPad (e.g. not wearing corrective lenses necessary to&#xD;
             read, inability to use both hands)&#xD;
&#xD;
         13. Subject considered unsuitable for participation in this clinical trial by PI, treating&#xD;
             clinician or research study staff&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Peacock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donna Edmonds</last_name>
    <phone>804-212-2975</phone>
    <email>dedmonds@brainboxinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Brown, MS</last_name>
    <phone>408-881-2611</phone>
    <email>abrown@brainboxinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas Lemar</last_name>
      <phone>913-588-3580</phone>
    </contact>
    <investigator>
      <last_name>Chad Cannon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Detroit Receiving</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Sabol</last_name>
    </contact>
    <investigator>
      <last_name>Robert Welch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Sabol</last_name>
    </contact>
    <investigator>
      <last_name>Robert Welch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinai Grace Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Sabol</last_name>
    </contact>
    <investigator>
      <last_name>Robert Welch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kian Merchant-Borna, MPH, MBA</last_name>
    </contact>
    <investigator>
      <last_name>Jeffrey Bazarian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Taylor</last_name>
    </contact>
    <investigator>
      <last_name>Adam Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Zamore</last_name>
    </contact>
    <investigator>
      <last_name>Danielle Sandsmark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Peter Smith (JPS) Health Network</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maximillian Masuda</last_name>
    </contact>
    <investigator>
      <last_name>James P d'Etienne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Ben Taub</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Keene</last_name>
      <phone>713-873-9818</phone>
    </contact>
    <investigator>
      <last_name>Zubaid Rafique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/St. Luke's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Keene</last_name>
    </contact>
    <investigator>
      <last_name>Zubaid Rafique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniella Rodriguez</last_name>
      <phone>540-588-3183</phone>
    </contact>
    <investigator>
      <last_name>Damon R Kuehl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TBI, mTBI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
    <mesh_term>Craniocerebral Trauma</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

